A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

NCT02681861 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects
Pharmacokinetics of ASP6294

Interventions

DRUG: ASP6294 Intravenous
DRUG: ASP6294 Subcutaneous
DRUG: Placebo Intravenous
DRUG: Placebo Subcutaneous

Sponsor

Astellas Pharma Europe B.V.